ReviewProgress in retinal and eye research2021
Corneal xenotransplantation: Where are we standing?
Review in Progress in retinal and eye research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Revolutionizing vision using corneal 3D printing.Trends in biotechnology · 2026Review
- Reframing Technology and Ethics in Corneal Xenotransplantation: A Scoping Review of Standards and Safety in Ophthalmology.Health care science · 2026Review
- A Comparative Analysis of Pig-to-Rhesus Corneal Xenotransplantation with Various Immunosuppressive Regimens.Korean journal of ophthalmology : KJO · 2026Article
- Exosome-based therapies for corneal disorders: current status and future perspectives.MedScience · 2026Review
- Bacterial synthesis of personalized biomimetic biological cornea.Bioactive materials · 2026Article
- Bioinspired Tissue Transparency: Achieving Sclera-to-Cornea Transplantation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Brain-dead humans as preclinical reference models for xenotransfusion: bridging nonhuman primates and clinical applications throughFrontiers in physiology · 2026Article
- Porcine Corneal Models as Translational Platforms for Innovative Therapies: Current Insights and Future Directions.Journal of functional biomaterials · 2025Review
- Xenogenic Corneal Lenticules (XENIA) - Biomechanical Characterization and Enzymatic Resistance Analysis.Translational vision science & technology · 2025Article
- The use of transgenic animals for xenotransplantation: An update.Animal models and experimental medicine · 2025Review
- Biosynthetic Collagen-Analog Hydrogels Stimulate Endogenous Regrowth of Rabbit Corneas: A Pilot Study.Veterinary sciences · 2025Article
- TLR3-overexpressing umbilical cord mesenchymal stromal cells suppress immune responses to attenuate high-risk corneal transplantation rejection.Stem cell research & therapy · 2025Article
- Corneal Endothelium Regeneration with Decellularized Porcine Corneal Extracellular Matrix Scaffolds.Tissue engineering and regenerative medicine · 2025Article
- Development of stromal corneal grafts using a novel decellularization method with sodium cocoyl glutamate onAnnals of translational medicine · 2025Article
- Interlamellar keratoplasty for implantation of decellularized porcine corneal lenticule in a rabbit for corneal thickening.Journal of materials science. Materials in medicine · 2025Article
- Immunology in corneal transplantation-From homeostasis to graft rejection.Transplantation reviews (Orlando, Fla.) · 2025Review
- Decellularization of camel corneas for tissue engineering applications.International ophthalmology · 2025Article
- Evaluating Therapeutic and Chemical Toxicity Using Organ-Cultured Porcine Corneas and Epithelial Wound Healing.Journal of visualized experiments : JoVE · 2025Article
- A pilot study for decellularizing porcine cornea for future use in corneal regeneration.PloS one · 2025Article
- Lamellar keratoplasty using acellular porcine corneal stroma for the treatment of corneal ulcers.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for alternatives to allotransplants is driven by the shortage of corneal donors and is demanding because of the limitations of the alternatives. Indeed, current progress in genetically engineered (GE) pigs, the introduction of gene-editing technology by clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and advanced immunosuppressants have made xenotransplantation a possible option for a human trial. Porcine corneal xenotransplantation is considered applicable because the eye is regarded as an immune-privileged site. Furthermore, recent non-human primate studies have shown long-term survival of porcine xenotransplants in keratoplasty. Herein, corneal immune privilege is briefly introduced, and xenogeneic reactions are compared with allogeneic reactions in corneal transplantation. This review describes the current knowledge on special issues of xenotransplantation, xenogeneic rejection mechanisms, current immunosuppressive regimens of corneal xenotransplantation, preclinical efficacy and safety data of corneal xenotransplantation, and updates of the regulatory framework to conduct a clinical trial on corneal xenotransplantation. We also discuss barriers that might prevent xenotransplantation from becoming common practice, such as ethical dilemmas, public concerns on xenotransplantation, and the possible risk of xenozoonosis. Given that the legal definition of decellularized porcine cornea (DPC) lies somewhere between a medical device and a xenotransplant, the preclinical efficacy and clinical trial data using DPC are included. The review finally provides perspectives on the current standpoint of corneal xenotransplantation in the fields of regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.